Indeed, the presence of high-frequency (and presumably tumor antigen-reactive) T-cell clones correlated with improved response in patients with prostate cancer treated with anti-CTLA-4 and a cancer vaccine18. The gene discussed is CTLA4; the disease is prostate carcinoma.